High relapse rate seen at week 72 for patients treated with R1626 combination therapy

Hepatology

Volumn 48, Issue 4, 2008, Pages 1349-1350

  Pockros, Paul ^a   Nelson, David ^b   Godofsky, Eliot ^c   Rodrigues Torres, Maribel ^d   Everson, Gregory T ^e   Fried, Michael W ^f   Ghalib, Reem ^g   Harrison, Stephen ^h   Nyberg, Lisa ⁱ   Shiffman, Mitchell L ^j   Chan, Anna ^k   Hill, George ^l  

^a SCRIPPS CLINIC   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Bach and Godofsky   (United States)

^d Fundacion de Investigacion de Diego San Juan   (Puerto Rico)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g METHODIST DALLAS MEDICAL CENTER   (United States)

^h BROOKE ARMY MEDICAL CENTER   (United States)

ⁱ KAISER PERMANENTE   (United States)

^j Virginia Commonwealth   (United States)

^k ROCHE BIOSCIENCE   (United States)

^l HOFFMANN LA ROCHE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PRODRUG; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; NUCLEOSIDE; PEGINTERFERON ALFA-2A;

DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HUMAN; LETTER; NEUTROPENIA; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; VIRUS LOAD; VIRUS RESISTANCE; DOSE RESPONSE; DRUG COMBINATION; INCIDENCE; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INCIDENCE; INTERFERON ALFA-2A; NUCLEOSIDES; POLYETHYLENE GLYCOLS; PRODRUGS; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 56849127356     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22593     Document Type: Letter

References (2)

1. Pockros PJ, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW, et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. HEPATOLOGY 2008;48:385-397.
2. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.